Jazz Pharmaceuticals Files 8-K Report

Ticker: JAZZ · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateApr 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory

TL;DR

Jazz Pharma filed an 8-K, likely containing important updates. Keep an eye out.

AI Summary

On April 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Jazz Pharmaceuticals is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on Other Events, Financial Statements and Exhibits, and a Regulation FD Disclosure.

What is the exact date of the earliest event reported?

The date of the earliest event reported is April 21, 2025.

Where is Jazz Pharmaceuticals plc's principal executive office located?

The principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, D04 E5W7.

What is the company's IRS Employer Identification No.?

The IRS Employer Identification No. is 98-1032470.

What is the Standard Industrial Classification code for Jazz Pharmaceuticals?

The Standard Industrial Classification code is 2834, which corresponds to PHARMACEUTICAL PREPARATIONS.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding Jazz Pharmaceuticals plc (JAZZ).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing